Tiziana Life Sciences has dosed the first three patients in a Phase 2a trial testing foralumab, a nasal spray antibody, for treating early-stage ALS. The Healey ALS MyMatch BANYAN trial will enroll 44 patients to evaluate safety, tolerability, and immune effects over 24 weeks. This study, co-funded by the ALS Association, aims to explore foralumab's impact on regulatory T cells and neuroinflammation, with results potentially advancing ALS treatment options. The trial is ongoing at multiple US centers and includes a community webinar on October 1 to discuss the science behind foralumab.
The ALS trial of nasal antibody foralumab by Tiziana Life Sciences is underway as of September 28, 2026. For readers following the health sector, here is Pluang's market snapshot as of Sep 28, 2026 19:53 WIB: out of 100 priced health-sector US stocks, 23 rose and 64 fell. Notable movers include Acadia Healthcare Company Inc (ACHC) at USD 27.57 with a 1-day change of -1.85%, AbCellera Biologics Inc (ABCL) at USD 12.47 with -1.81%, and Aurora Cannabis Inc (ACB) at USD 4.04 with -1.46%.
Ipsos achieved 2.0% organic revenue growth in Q3 2026, up from 0.8% in H1, driven by strong performances in EMEA, China, and citizen-related activities. The company updated its 2026 organic growth target to 1.2%-1.5%, reflecting improved momentum and...
Ipsos posted €636.2 million revenue in Q3 2026 with 2.0% organic growth, up from 0.8% in H1, led by strong performances in EMEA, China, and its Citizens business. The company updated its full-year organic growth outlook to 1.2%-1.5%, citing ongoing g...
Signify reported third-quarter 2026 results with sales of EUR 1,367 million, a slight decline in comparable sales by 3.4%, but improved adjusted EBITA of EUR 145 million and a margin increase to 10.6%. Net income rose to EUR 88 million and free cash ...
Sika AG posted a 4.8% sales increase in local currencies for the first nine months of 2026, reaching CHF 8.71 billion despite currency headwinds. The company saw organic growth of 3.5% and improved material margins to 55.4%, with EBITDA rising 1.9% t...
Sika reported a 4.8% sales increase in local currencies for the first nine months of 2026, reaching CHF 8.71 billion despite a negative currency effect. The company improved its material margin to 55.4% and maintained an EBITDA margin of 19.2%, with ...
